Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Capital Expenditures (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Capital Expenditures for 6 consecutive years, with -$3.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 3887.18% year-over-year to -$3.0 million, compared with a TTM value of $129000.0 through Dec 2025, down 27.12%, and an annual FY2025 reading of $129000.0, down 27.12% over the prior year.
  • Capital Expenditures was -$3.0 million for Q4 2025 at Cytek Biosciences, down from $657000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $9.5 million in Q4 2022 and bottomed at -$3.0 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $511400.0, with a median of $211000.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures skyrocketed 6999.25% in 2022, then plummeted 3887.18% in 2025.
  • Year by year, Capital Expenditures stood at $134000.0 in 2021, then surged by 6999.25% to $9.5 million in 2022, then crashed by 100.59% to -$56000.0 in 2023, then soared by 239.29% to $78000.0 in 2024, then tumbled by 3887.18% to -$3.0 million in 2025.
  • Business Quant data shows Capital Expenditures for CTKB at -$3.0 million in Q4 2025, $657000.0 in Q3 2025, and $1.6 million in Q2 2025.